Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 10, 2000, Pages 1109-1120

  Van Hecken, A ^a   Schwartz, J I ^a   Depre, M ^a   De Lepeleire, I ^a   Dallob, A ^a   Tanaka, W ^a   Wynants, K ^a   Buntinx, A ^a   Arnout, J ^a   Wong, P H ^a   Ebel, D L ^a   Gertz, B J ^a   De Schepper, P J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MELOXICAM; NAPROXEN; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE B2;

ADULT; ANALGESIA; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME INHIBITOR INTERACTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION; URINARY EXCRETION;

ADOLESCENT; ADULT; BLEEDING TIME; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DINOPROSTONE; FEMALE; HUMANS; IBUPROFEN; ISOENZYMES; LACTONES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SULFONES; THIAZINES; THIAZOLES; THROMBOXANE B2;

EID: 0033673612     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. New insights into the mode of action of anti-inflammatory drugs
2. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs
3. Human cyclooxygenase-2 cDNA
4. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells
5. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins
6. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production
7. Cyclooxygenase-1 and cyclooxygenase-2: Selectivity of widely used nonsteroidal anti-inflammatory drugs
8. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
9. Differentiating among nonsteroidal anti-inflammatory drugs by pharmacokinetic and pharmacodynamic profiles
10. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins
11. Scientific rationale for specific inhibition of COX-2
12. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
13. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
14. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
15. Rofecoxib (Vioxx, MK-0966; 4-(4'-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
16. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
17. Demonstration of specific COX-2 inhibition by MK-0966 in humans with supratherapeutic doses
18. Treatment with MK-966 (VIOXX(TM)), a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis of the knee and hip, that was sustained over six months
19. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than aspirin or ibuprofen
20. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. Does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg T.I.D
21. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. Over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg T.I.D
22. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
23. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastrododenal mucosa of patients with osteo arthritis
24. Mesure du temps de saignement par la methode d'Ivy Nelson
25. Graphical display of means
26. Evaluating overlapping confidence intervals
27. Meloxicam: Influence on arachidonic acid metabolism. Part I. In vitro findings
28. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state
29. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial
30. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
31. 2 metabolites in humans
32. 2 in man
33. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease
34. The clinical significance of inhibition of renal prostaglandin synthesis
35. Estimated rate of prostacyclin secretion into the circulation of normal man
36. Localisation of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
37. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
38. Low-dose aspirin in patients recovering from myocardial infarction: Evidence for a selective inhibition of thromboxane-related platelet function
39. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
40. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus
41. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance
42. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man
43. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
44. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
45. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
46. Effects of ketoprofen and ibuprofen on platelet aggregation and prostanoid formation in man
47. Dissociation of inhibitory effects of low-dose ASA on thromboxane production and platelet aggregation in ischemic stroke patients
48. 2) synthesis in healthy humans. Paper presented at the annual meeting of the American Gastroenterological Association
49. Arachidonic acid-induced platelet aggregation and prostanoid formation in whole blood in relation to plasma concentration of indomethacin
50. Effects of repeated oral doses of fenflumizole on platelet aggregation and thromboxane formation in man ex vivo
51. Intravenous diclofenac coupled with PCA fentanyl for pain relief after total hip replacement
52. Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers
53. Effect of a non-steroidal anti-inflammatory drug, diclofenac, on hemostasis in patients undergoing total hip replacement